Latest News

IGT leaders recently penned a piece exploring the strides being made in gene therapy and highlighting the ongoing challenges that must be...

As Newborn Screening Awareness Month concludes, IGT applauds the tireless work of advocates who dedicate themselves 365 days of the year...

Author: Andrea Matthews, Founder, Children’s Sickle Cell Foundation, Inc.   Newborn screening (NBS) is an important public health measure...

Newborn screening is critical to ensure faster access to treatment and cures for genetic conditions. This September, IGT is recognizing...

On Friday, June 28, the House Budget Committee Health Care Task Force hosted a roundtable entitled, “Paying for 21st Century Cures:...

The Centers for Medicare and Medicaid Services (CMS) may soon finalize proposed changes to the Medicaid Drug Rebate Program (MDRP) that,...

On May 9, the Institute for Gene Therapy (IGT), along with the Alliance for Regenerative Medicine (ARM), held a Congressional briefing...

Today, Senators Markwayne Mullin (R-OK), Kyrsten Sinema (AZ), Tim Scott (SC), and Maggie Hassan (NH) introduced the Senate companion to...

By Regina Hartfield, President and CEO, Sickle Cell Disease Association of America, Inc. This year, we celebrate a landmark step forward...

Last week, the Institute for Gene Therapies (IGT) sent a response to the Health Resources and Services Administration (HRSA) Request for...

As we recognize National Minority Health Month (NMHM), the Institute for Gene Therapies (IGT)’s Scientific, Academic and Medical Advisory...

On February 14, IGT Chairman Erik Paulsen joined a panel of experts at the American Enterprise Institute’s (AEI) event, “Navigating...

This week, the Institute for Gene Therapies (IGT) sent a response to the Senate Health, Education, Labor, and Pensions (HELP) Committee...

On December 13, the Institute for Gene Therapies held its third Congressional Briefing of 2023, "Realizing the Promise of Gene Therapy:...

Gene therapies are changing the way we treat diseases by targeting the cause of a disease directly at the DNA level, rather than...

By IGT Director of Health Policy & Advocacy John Feore This month, I had the opportunity to participate in the American Society of Cell...

On June 26th, the Institute for Gene Therapies hosted its second Congressional Briefing focused on the promise of gene therapy, its...

Lauren Holder, Huntington’s Disease Patient Advocate and member of the Institute for Gene Therapy Patient Advocacy Advisory Council,...

Patients, researchers, and other key stakeholders are weighing in on the importance of the Medicaid VBPs for Patients Act, or the MVP Act...

Today, the Institute for Gene Therapies (IGT) sent a letter to Congress applauding Representatives Brett Guthrie (R-KY), Anna Eshoo...

By Nate Plasman This February, I had the opportunity to travel to Capitol Hill to participate in the Institute for Gene Therapy’s...

By IGT Chairman Erik Paulsen As more breakthrough gene therapies are developed and brought to market, a critical element in bringing...

On February 21, the Institute for Gene Therapies hosted a panel discussion on the science of gene therapy, its impact on patients and...

IGT Scientific, Academic, and Medical Council Chair Dr. Donna Christian-Christensen recently wrote an opinion piece for Inside Sources,...

By IGT Scientific, Academic & Medical Advisory Council Chair Donna M. Christensen Last week, during the Congressional Black Caucus...

Earlier this month the Institute for Gene Therapies submitted a comment letter to the Centers for Medicare and Medicaid Services (CMS) on...

Gene therapies present a unique opportunity to change the way we treat diseases. Given the complex nature of these transformative...

On April 28th, IGT Chairman Paulsen joined leaders in Congress on the Healthy Future Task Force Treatments Subcommittee Roundtable. The...

Last week, IGT joined many organizations in expressing concern about a policy proposal that would restrict patients’ access to certain...

By IGT Scientific, Academic & Medical Advisory Council Chair Donna M. Christensen April is National Minority Health Month, an important...

WASHINGTON, DC (April 5, 2022) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

By Deborah Fowler, President & Founder of Soft Bones Rare Disease Day is a critical awareness day for many patients and families who are...

By IGT Patient Advocacy Advisory Council Member and Huntington's Disease Patient Advocate Seth Rotberg As we enter the third year of the...

WASHINGTON, DC (November18, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

WASHINGTON, DC (August 6, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

TX RARE works to improve access and health outcomes for nearly three million Texans living with rare diseases. Khrystal Davis, Founder of...

IGT is proud to have the National Human Genome Center of Howard University as a member of our Scientific, Academic & Medical Council....

WASHINGTON, DC (April 27, 2021) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

By IGT Scientific, Academic and Medical Council Chair Donna M. Christensen April is National Minority Health Month, a time to recognize...

Gene therapies offer a completely new way of treating a range of serious diseases. But before we can realize their full potential, a...

This Sunday, February 28th marks the 14th Rare Disease Day. Patients, advocates, providers, and others around the world recognize this...

WASHINGTON, DC (December 23, 2020) – Today, the Institute for Gene Therapies (IGT) Chairman Congressman Erik Paulsen issued the following...

CureDuchenne’s mission is to improve the lives of everyone affected by Duchenne through accelerating research to find the cure, improving...

September is Newborn Screening Awareness Month, a dedicated time to educate the public about this critical screening. IGT advocates for...

By Jennifer McNary, mother of two sons with Duchenne muscular dystrophy, patient advocate and founder of One Rare. For all the incredible...

One of our founding Patient Advisory Council Members, the EveryLife Foundation for Rare Diseases, is a 501(c)(3) nonprofit, nonpartisan...

Proposed rule advances longstanding priority for gene therapy stakeholders FOR IMMEDIATE RELEASE July 20, 2020 CONTACT: Macey Kostbar,...

On Monday, July 13, the Institute for Gene Therapies (IGT) held a conversation with recognized experts on the CMS proposed rule that...

On Monday, July 13, 2020 at 4 PM Eastern Time, the Institute for Gene Therapies (IGT) will host a conversation with recognized experts...

FOR IMMEDIATE RELEASE CONTACT: Macey Kostbar msevcik@gene-therapies.org WASHINGTON, DC (June 18, 2020) – Below is a statement from the...